CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.88 billion. The enterprise value is $2.74 billion.
| Market Cap | 1.88B |
| Enterprise Value | 2.74B |
Important Dates
The last earnings date was Wednesday, April 30, 2025, after market close.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | Mar 14, 2025 |
Share Statistics
CONMED has 30.94 million shares outstanding. The number of shares has decreased by -1.41% in one year.
| Current Share Class | 30.94M |
| Shares Outstanding | 30.94M |
| Shares Change (YoY) | -1.41% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 118.24% |
| Float | 30.68M |
Valuation Ratios
The trailing PE ratio is 15.93 and the forward PE ratio is 13.70. CONMED's PEG ratio is 1.58.
| PE Ratio | 15.93 |
| Forward PE | 13.70 |
| PS Ratio | 1.43 |
| Forward PS | 1.34 |
| PB Ratio | 1.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.42 |
| P/OCF Ratio | 10.47 |
| PEG Ratio | 1.58 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.26, with an EV/FCF ratio of 16.62.
| EV / Earnings | 23.04 |
| EV / Sales | 2.08 |
| EV / EBITDA | 12.26 |
| EV / EBIT | 17.94 |
| EV / FCF | 16.62 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.91.
| Current Ratio | 2.26 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.91 |
| Debt / EBITDA | 3.84 |
| Debt / FCF | 5.42 |
| Interest Coverage | 4.24 |
Financial Efficiency
Return on equity (ROE) is 12.96% and return on invested capital (ROIC) is 5.13%.
| Return on Equity (ROE) | 12.96% |
| Return on Assets (ROA) | 4.14% |
| Return on Invested Capital (ROIC) | 5.13% |
| Return on Capital Employed (ROCE) | 7.57% |
| Revenue Per Employee | $337,435 |
| Profits Per Employee | $30,449 |
| Employee Count | 3,900 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, CONMED has paid $26.53 million in taxes.
| Income Tax | 26.53M |
| Effective Tax Rate | 18.26% |
Stock Price Statistics
The stock price has decreased by -14.66% in the last 52 weeks. The beta is 1.19, so CONMED's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -14.66% |
| 50-Day Moving Average | 56.23 |
| 200-Day Moving Average | 66.12 |
| Relative Strength Index (RSI) | 63.73 |
| Average Volume (20 Days) | 554,511 |
Short Selling Information
The latest short interest is 846,967, so 2.74% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.74% |
| Short % of Float | 2.76% |
| Short Ratio (days to cover) | 4.23 |
Income Statement
In the last 12 months, CONMED had revenue of $1.32 billion and earned $118.75 million in profits. Earnings per share was $3.81.
| Revenue | 1.32B |
| Gross Profit | 740.62M |
| Operating Income | 152.52M |
| Pretax Income | 123.90M |
| Net Income | 118.75M |
| EBITDA | 223.20M |
| EBIT | 152.52M |
| Earnings Per Share (EPS) | $3.81 |
Balance Sheet
The company has $35.49 million in cash and $892.16 million in debt, giving a net cash position of -$856.67 million or -$27.69 per share.
| Cash & Cash Equivalents | 35.49M |
| Total Debt | 892.16M |
| Net Cash | -856.67M |
| Net Cash Per Share | -$27.69 |
| Equity (Book Value) | 977.64M |
| Book Value Per Share | 31.61 |
| Working Capital | 355.85M |
Cash Flow
In the last 12 months, operating cash flow was $179.38 million and capital expenditures -$14.83 million, giving a free cash flow of $164.55 million.
| Operating Cash Flow | 179.38M |
| Capital Expenditures | -14.83M |
| Free Cash Flow | 164.55M |
| FCF Per Share | $5.32 |
Margins
Gross margin is 56.28%, with operating and profit margins of 11.59% and 9.02%.
| Gross Margin | 56.28% |
| Operating Margin | 11.59% |
| Pretax Margin | 11.04% |
| Profit Margin | 9.02% |
| EBITDA Margin | 16.96% |
| EBIT Margin | 11.59% |
| FCF Margin | 12.50% |
Dividends & Yields
This stock pays an annual dividend of $0.80, which amounts to a dividend yield of 1.32%.
| Dividend Per Share | $0.80 |
| Dividend Yield | 1.32% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 20.99% |
| Buyback Yield | 1.41% |
| Shareholder Yield | 2.73% |
| Earnings Yield | 6.32% |
| FCF Yield | 8.76% |
Analyst Forecast
The average price target for CONMED is $62.20, which is 2.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $62.20 |
| Price Target Difference | 2.42% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 2.29 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | 8 |